OBJECT: The goal of this study was to investigate outcomes in @entity1 with @entity5513 ( @entity5513 ) who were treated with fractionated stereotactic radiotherapy (SRT). METHODS: One hundred one @entity1 with @entity5513 were treated with fractionated SRT at a radiation level of 40 to 50 Gy administered in 20 to 25 fractions over a 5- to 6-week period. The median @entity5 size in these @entity1 was 19 mm (range 3-40 mm), and 27 @entity5 were larger than 25 mm. @entity1 were consistently followed up using magnetic resonance imaging every 6 months for 5 years in principle. The median follow-up period was 45 months. The actuarial 5-year rate of @entity5 control (no growth > 2 mm and no requirement for salvage surgery) was 91.4% (95% confidence interval 85.2-97.6%). Three @entity1 with progressive @entity5 underwent salvage @entity5 resection. The actuarial 5-year rate of useful hearing preservation (Gardner-Robertson Class I or II) was 71%. The observed complications of fractionated SRT included transient @entity2103 (4% of @entity1 ), trigeminal @entity16 (14% of @entity1 ), and balance disturbance (17% of @entity1 ). No new permanent @entity425 occurred after fractionated SRT. Eleven @entity1 (11%) who had progressive communicating @entity1276 ( @entity8884 ) and no evidence of @entity5 growth after fractionated SRT required a shunt. The symptoms of this type of @entity1276 were similar to those of normal-pressure @entity1276 and occurred 4 to 20 months (median 12 months) after fractionated SRT. The mean size (+/- standard deviation) of @entity5 causing symptomatic @entity1276 (25.5 +/- 7.8 mm) was significantly larger than that of other @entity5 (18.2 +/- 8.7 mm) (p = 0.011). Only four of the 72 @entity1 with @entity5 smaller than 25 mm in maximum diameter received a shunt. CONCLUSIONS: Fractionated SRT resulted in an excellent @entity5 control rate, even for relatively large @entity5 , and produced a high rate of hearing preservation that was comparable to the best results of single-fraction radiosurgery. The progression of communicating @entity1276 should be monitored closely, particularly in @entity1 harboring a large @entity5513 .

Management of XXXX by fractionated stereotactic radiotherapy and associated @entity8884 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5513 :: ('MESH:D009464', 'Disease') :: ['VS', 'vestibular schwannoma'] @entity1276 :: ('MESH:D006849', 'Disease') :: ['hydrocephalus'] @entity8884 :: ('MESH:D008286', 'Disease') :: ['cerebrospinal fluid malabsorption'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy'] @entity2103 :: ('MESH:D005155', 'Disease') :: ['facial nerve palsy'] @entity425 :: ('MESH:D018908', 'Disease') :: ['facial weakness']
@entity5513 :: (MESH:D009464,Disease) :: ['vestibular schwannoma']
